EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant

Nicolas Meurisse, Markoen Mertens, Steffen Fieuws, Nicholas Gilbo, Ina Jochmans, Jacques Pirenne, Diethard Monbaliu

JAMA Network Open · 28.02.2023 · 6 (2) · e230819

DOI: 10.1001/jamanetworkopen.2023.0819 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 28.02.2023. Verfasst von Nicolas Meurisse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Abdominal Transplantation, Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuve…. Hauptthemen laut MEDLINE: Anesthesia, Liver Transplantation, Reperfusion Injury. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In a porcine model of liver transplant, a combined drug approach that targeted the donor graft and graft recipient reduced ischemia-reperfusion injury, a major hurdle to the success of liver transplant.

Objective

To assess the effect of a clinical form of a perioperative combined drug approach delivered immediately before implantation to the procured liver and to the liver recipient on the degree of ischemia-reperfusion injury. Design, Setting, and Participants This unicentric, investigator-driven, open-label randomized clinical trial with 2 parallel arms was conducted in Belgium from September 2013 through February 2018, with 1-year follow-up. Adults wait-listed for a first solitary full-size liver transplant were screened for eligibility. Exclusion criteria were acute liver failure, kidney failure, contraindication to treatment, participation in another trial, refusal, technical issues, and death while awaiting transplant. Included patients were enrolled and randomized at the time of liver offer. Data were analyzed from May 20, 2019, to May 27, 2020.

Interventions

Participants were randomized to a combined drug approach with standard of care (static cold storage) or standard of care only (control group). In the combined drug approach group, following static cold preservation, donor livers were infused with epoprostenol (ex situ, portal vein); recipients were given oral α-tocopherol and melatonin prior to anesthesia and intravenous antithrombin III, infliximab, apotransferrin, recombinant erythropoietin-β, C1-inhibitor, and glutathione during the anhepatic and reperfusion phase. Main Outcomes and Measures The primary outcome was the posttransplant peak serum aspartate aminotransferase (AST) level within the first 72 hours. Secondary end points were the frequencies of postreperfusion syndrome, ischemia-reperfusion injury score, early allograft dysfunction, surgical complications, ischemic cholangiopathy, acute kidney injury, acute cellular rejection, and graft and patient survival.

Results

Of 93 randomized patients, 21 were excluded, resulting in 72 patients (36 per study arm) in the per protocol analysis (median recipient age, 60 years [IQR, 51.7-66.2 years]; 52 [72.2%] men). Peak AST serum levels were not different in the combined drug approach and control groups (geometric mean, 1262.9 U/L [95% CI, 946.3-1685.4 U/L] vs 1451.2 U/L [95% CI, 1087.4-1936.7 U/L]; geometric mean ratio, 0.87 [95% CI, 0.58-1.31]; P = .49) (to convert AST to μkat/L, multiply by 0.0167). There also were no significant differences in the secondary end points between the groups. Conclusions and Relevance In this randomized clinical trial, the combined drug approach targeting the post–cold storage graft and the recipient did not decrease ischemic-reperfusion injury. The findings suggest that in addition to a downstream strategy that targets the preimplantation liver graft and the graft recipient, a clinically effective combined drug approach may need to include an upstream strategy that targets the donor graft during preservation. Dynamic preservation strategies may provide an appropriate delivery platform. Trial Registration ClinicalTrials.gov Identifier: NCT02251041

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnesthesiaLiver TransplantationReperfusion InjuryAnimalsFemaleHumansMaleLiverPharmaceutical PreparationsSwineMiddle AgedAged

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Laboratory of Abdominal Transplantation, Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
  • Department of Abdominal Transplant Surgery and Transplant Coordination, University Hospitals Leuven, Leuven, Belgium.
  • Department of Abdominal Surgery and Transplantation, CHU de Liège, University of Liège, Liège, Belgium.
  • Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven-University of Leuven, Leuven, Belgium.

Zitieren

APA

Meurisse, N., Mertens, M., Fieuws, S., Gilbo, N., Jochmans, I., Pirenne, J., & Monbaliu, D. (2023). Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant. JAMA Network Open, 6(2), e230819. https://doi.org/10.1001/jamanetworkopen.2023.0819

Vancouver

Meurisse N, Mertens M, Fieuws S, Gilbo N, Jochmans I, Pirenne J, et al. Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant. JAMA Network Open. 2023;6(2):e230819. doi:10.1001/jamanetworkopen.2023.0819

BibTeX
@article{Meurisse2023,
  author = {Meurisse, Nicolas and Mertens, Markoen and Fieuws, Steffen and Gilbo, Nicholas and Jochmans, Ina and Pirenne, Jacques and Monbaliu, Diethard},
  title = {Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {2},
  pages = {e230819},
  doi = {10.1001/jamanetworkopen.2023.0819}
}
Kostenlos starten →